

## Special Issue

# Molecular Mechanisms of Cancer Development and Metastasis

### Message from the Guest Editors

The spread of cancer cells, a process called metastasis, is the main reason for the majority of cancer-related deaths, and most current therapies are incapable of efficiently treating metastatic cancers. This is due to our lack of understanding of the complex biological process that occurs during metastasis. Therefore, the comprehensive identification of molecular mechanisms underlying cancer development and metastasis is essential to devise new therapies. This Special Issue refers to the underlying biological processes that lead to the development and spread of cancer cells; the key areas include genetic and nongenetic molecular alterations, dysregulated signaling pathways, angiogenesis, cell migration and invasion, epithelial-to-mesenchymal transition (EMT) and immune system evasion.

---

### Guest Editors

Dr. Babak Behnam

1. Avicenna Biotech Research, Clarksburg, MD 20871, USA
2. Floret Center for Advanced Genomics & Bioinformatics Research Center, Lagos 100282, Nigeria

Dr. Hassan Fazilaty

Department of Molecular Life Sciences, University of Zurich, 8006 Zurich, Switzerland

---

### Deadline for manuscript submissions

closed (31 July 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/173471](https://mdpi.com/si/173471)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)